Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965818 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT04965818 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 38 participants.
The verdict
NCT04965818, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
Interventions
- DRUG Futibatinib and Binimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2023-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04965818
The ClinicalTrials.gov registry entry for NCT04965818 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Futibatinib and Binimetinib is the first listed.
NCT04965818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04965818 about?
NCT04965818 is a clinical study titled "Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer". Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
What is the current status of trial NCT04965818?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2021-09-20. Estimated completion is 2023-09-21.
What interventions are being tested in trial NCT04965818?
The interventions under investigation include: Futibatinib and Binimetinib (DRUG).
Who is sponsoring clinical trial NCT04965818?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.